Pharma and Biotech Daily: September 24, 2025

Episode: FDA Revives Drug for Autism, Tylenol Pregnancy Warning, and More!
Host: Pharma and BioTech News

Episode Overview

This episode delivers a fast-paced roundup of the latest and most impactful developments in the pharma and biotech industry. Key topics include the FDA’s surprising move to revive an old GlaxoSmithKline drug as a potential autism treatment, new warnings regarding acetaminophen (Tylenol) use during pregnancy, updates on regulatory and manufacturing challenges for major drugs, scrutiny on vaccine guidelines and critics, and highlights of industry credentials and upcoming events.

Key Discussion Points & Insights

1. FDA Revives Dormant Autism Drug (00:10)

• Main Point:
  The FDA has decided to revisit a previously dormant GlaxoSmithKline medication, exploring its application as a treatment for autism spectrum disorder.
• Insight:
  This move could signal renewed interest in repurposing or re-evaluating shelved pharmaceuticals, potentially accelerating research in challenging therapeutic areas.
• Quote:
  "The FDA has revived a long dormant drug from GlaxoSmithKline as a potential treatment for autism." — [A, 00:12]

2. Tylenol Use in Pregnancy Under Scrutiny (00:27)

• Main Point:
  The FDA released a statement regarding a possible link between acetaminophen (Tylenol) use during pregnancy and the risk of neurological and developmental defects in children.
• Insight:
  This raises significant public health questions and may change clinical and consumer guidelines for over-the-counter pain relievers during pregnancy.
• Quote:
  "...the potential link between the use of Tylenol and other acetaminophen products during pregnancy and neurological and developmental defects in children." — [A, 00:29]

3. Scholar Rock’s Spinal Muscular Atrophy Drug Hits Manufacturing Snag (00:49)

• Main Point:
  Scholar Rock’s candidate for spinal muscular atrophy faced a setback due to issues at its manufacturing site.
• Context:
  Such manufacturing problems can delay access to promising therapies, impacting patients and companies alike.
• Quote:
  "Scholar Rock's spinal muscular atrophy drug faced manufacturing site issues..." — [A, 00:51]

4. Lexicon’s Type 1 Diabetes Drug Encounters Regulatory Delays (01:01)

• Main Point:
  Lexicon Pharmaceuticals reported regulatory delays with its type 1 diabetes therapy.
• Insight:
  Regulatory hurdles remain a frequent obstacle in drug development pipelines, especially for chronic diseases.
• Quote:
  "...Lexicon's type 1 diabetes drug experienced regulatory delays..." — [A, 01:03]

5. Spotlight on Merck’s ProQuad Vaccine Amid Changing Guidelines (01:10)

• Main Point:
  The history and current considerations of Merck’s ProQuad vaccine are examined as vaccine guidelines continue to evolve.
• Quote:
  "Merck's Proquad vaccine history was examined amid changing vaccine guidelines." — [A, 01:12]

6. Kennedy’s Criticism of Childhood Vaccines Addressed (01:17)

• Main Point:
  Commentary is offered on public figures, specifically Kennedy, who have criticized childhood vaccines, an often-polarizing topic.
• Quote:
  "Kennedy's criticism of childhood vaccines was also discussed." — [A, 01:18]

7. Industry Credentials and Upcoming Events (01:23)

• Main Point:
  The podcast highlights Biotility’s credential programs for bioscience professionals and showcases a variety of other biopharma news and events.
• Quote:
  "Biotility offers industry recognized credentials for bioscience professionals while a variety of biopharma news and upcoming events were highlighted." — [A, 01:23]

Notable Quotes & Memorable Moments

• On the Autism Drug Revival:
  "The FDA has revived a long dormant drug from GlaxoSmithKline as a potential treatment for autism." — [A, 00:12]

• On Tylenol’s Pregnancy Warning:
  "...the potential link between the use of Tylenol and other acetaminophen products during pregnancy and neurological and developmental defects in children." — [A, 00:29]

• On Industry Ups and Downs:
  "Scholar Rock's spinal muscular atrophy drug faced manufacturing site issues..." — [A, 00:51]
  "...Lexicon's type 1 diabetes drug experienced regulatory delays..." — [A, 01:03]

Timed Segment Highlights

• 00:10 — FDA revives dormant GlaxoSmithKline autism drug
• 00:27 — FDA commentary on Tylenol and pregnancy
• 00:49 — Scholar Rock’s manufacturing setback
• 01:01 — Lexicon’s regulatory delay
• 01:10 — Merck’s ProQuad and vaccine guidelines
• 01:17 — Addressing Kennedy’s criticism of vaccines
• 01:23 — Credentials for bioscience professionals and upcoming industry events

Closing Tone

The episode offers concise, credible, and well-sourced daily updates, maintaining a balanced and informative tone suitable for industry professionals and engaged listeners seeking quick insights into pressing pharma and biotech developments.